Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Regeneron Pharmaceuticals380 enrolled

Overview

To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

380

Conditions

Atopic Dermatitis

Interventions

DupilumabDRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

The inclusion criteria included, but were not limited to, the following: 1. Chronic Atopic Dermatitis that had been present for at least 3 years 2. History of inadequate response to out-patient treatment with topical medications, or for whom topical treatments were otherwise inadvisable (e.g, because of important side effects or safety risks) 3. Willing and able to comply with all clinic visits and study-related procedures The exclusion criteria included, but were not limited to, the following: 1. Prior treatment with dupilumab (REGN668/SAR231893) 2. Presence of certain laboratory abnormalities at the screening visit 3. Treatment with an investigational drug within 8 weeks of baseline visit 4. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit 5. Certain other treatments and medical procedures undertaken within a particular time frame prior to the baseline visit 6. Known history of human immunodeficiency virus (HIV) infection 7. History of malignancy within 5 years before the baseline visit (with certain exceptions) 8. Planned surgical procedure during the length of the study 9. High risk of parasite infection 10. Any other medical or psychological condition that in the opinion of the investigator or the sponsor's medical monitor, would place the participants at risk, interfere with participation in the study or interfere with interpretation of study results 11. Pregnant or breast-feeding women

Locations (84)

Outcomes

Primary Outcomes

Percent Change in Eczema Area and Severity Index Score (EASI) From Baseline to Week 16

Time frame: Baseline to Week 16

Secondary Outcomes

Percentage of Participants Who Achieved Investigator's Global Assessment (IGA) Response at Week 16

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a static 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.

Time frame: Week 16

Percentage of Participants Who Achieved IGA Score Reduction of ≥2 at Week 16

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic success is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score reduction from baseline of ≥2 points at Week 16 were reported. Values after first rescue medication were set to missing and participants with missing IGA score at Week 16 were treated as a non-responders.

Time frame: Week 16

Percent Change in Peak Weekly Averaged Pruritus Numerical Rating Scores (NRS) From Baseline to Week 16

Pruritus NRS is an assessment tool that is used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Birmingham, Alabama, United States

Unnamed facility

Mobile, Alabama, United States

Unnamed facility

Tucson, Arizona, United States

Unnamed facility

Bakersfield, California, United States

Unnamed facility

San Diego, California, United States

Unnamed facility

Santa Monica, California, United States

Unnamed facility

Jacksonville, Florida, United States

Unnamed facility

Ormond Beach, Florida, United States

Unnamed facility

Skokie, Illinois, United States

Unnamed facility

New Orleans, Louisiana, United States

...and 74 more locations

Time frame: Baseline to Week 16

Absolute Change in Peak Weekly Averaged Pruritus NRS From Baseline to Week 16

Time frame: Baseline to Week 16

Absolute Change in EASI Score From Baseline to Week 16

Time frame: Baseline to Week 16

Percent Change in SCORing Atopic Dermatitis (SCORAD) Scores From Baseline to Week 16

SCORAD is a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

Time frame: Baseline to Week 16

Absolute Change in SCORAD Scores From Baseline to Week 16

Time frame: Baseline to Week 16

Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in EASI Score (EASI-50, EASI-75 and EASI-90 Respectively) at Week 16

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score range from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50, EASI-75 and EASI-90 responders were the participants who achieved ≥50%, ≥75% and ≥90% overall improvement in EASI score respectively from baseline to Week 16.

Time frame: Week 16

Percentage of Participants Who Achieved 50%, 75% and 90% Reduction From Baseline in SCORAD Score (SCORAD-50, SCORAD-75 and SCORAD-90 Respectively) at Week 16

Time frame: Week 16

Percent Change in Patient Oriented Eczema Measure (POEM) Scores From Baseline to Week 16

POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]).

Time frame: Baseline to Week 16

Absolute Change in POEM Scores From Baseline to Week 16

Time frame: Baseline to Week 16

Changes in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations, and Lichenification) From Baseline to Week 16

Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0=none, 1=mild, 2=moderate and 3=severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).

Time frame: Baseline to Week 16

Changes in GISS Cumulative Score From Baseline to Week 16

Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none,1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).

Time frame: Baseline to Week 16